Metabolic · In Clinical Trials
Beinaglutide
No lawful US pathway
01 · Overview
Beinaglutide is a recombinant human GLP-1 (rhGLP-1) used in China as a treatment for type 2 diabetes (PMID 39239660). Unlike long-acting GLP-1 analogues, it is short-acting and is injected subcutaneously three times daily, reaching peak levels about 15 minutes after injection (PMID 39239660).
Like native GLP-1, it stimulates glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety.
02 · Research summary & key findings
In a 16-week phase 3 trial in non-diabetic Chinese adults with overweight or obesity, beinaglutide plus lifestyle intervention reduced body weight by 6.0 percent versus 2.4 percent with placebo, with transient nausea in about half of patients (PMID 37945546). A meta-analysis of six randomized trials found modest reductions in weight, BMI, and waist circumference but no significant differences in glycemic and other metabolic endpoints versus controls over 12 to 24 weeks (PMID 40487607). Published evidence comes mainly from Chinese studies, and it is not approved in the United States or European Union.
03 · Regulatory status
Beinaglutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Beinaglutide is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Metabolic
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Beinaglutide is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study Diabetes Obes Metab, 2024. PMID 37945546
- [2]Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight/obesity: results from a phase I clinical trial Front Pharmacol, 2024. PMID 39239660
- [3]Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis World J Diabetes, 2025. PMID 40487607
Primary literature
- PubMed: "Beinaglutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Beinaglutide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Beinaglutide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.